Homogeneous antibody-drug conjugates with dual payloads: potential, methods and considerations
The development of site-specific dual-payload antibody-drug conjugates (ADCs) represents a potential advancement in targeted cancer therapy, enabling the simultaneous delivery of two distinct drugs into the same cancer cells to overcome payload resistance and enhance therapeutic efficacy. Here, we e...
Saved in:
| Main Authors: | Miao Wen, Abigail Yu, Young Park, Daniel Calarese, Hans-Peter Gerber, Gang Yin |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | mAbs |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/19420862.2025.2498162 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Antibody-drug conjugates in cancer therapy: applications and future advances
by: Rou Long, et al.
Published: (2025-05-01) -
Exploration of the antibody–drug conjugate clinical landscape
by: Heather Maecker, et al.
Published: (2023-12-01) -
The Impact of Conjugation Mode and Site on Tubulysin Antibody‐Drug‐Conjugate Efficacy and Stability
by: Sayumi Yamazoe, et al.
Published: (2025-08-01) -
Therapeutic index improvement of antibody-drug conjugates
by: Hans-Peter Gerber, et al.
Published: (2023-12-01) -
Understanding the Toxicity Profile of Approved ADCs
by: Pablo Ballestín, et al.
Published: (2025-02-01)